ImmuCell Corporation
ICCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 51.6% | -5.9% | -3.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 30% | 25.2% | 41.2% | 45% |
| EBITDA | $0 | -$0 | $0 | $0 |
| % Margin | 4% | -14.3% | 1.9% | 14% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.1% | -33.1% | -13.4% | -0.4% |
| EPS Diluted | -0.26 | -0.75 | -0.32 | -0.01 |
| % Growth | 65.3% | -134.4% | -3,006.8% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |